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ABSTRACT
Objective: The objective of this study is to assess adverse drug reaction (ADR) profile of the drugs prescribed to treat Coronavirus Disease (COVID-19) 
positive patients and to determine whether ADRs are associated with any comorbidities.
Methods: A cross-sectional study was done with Laboratory confirmed COVID-19 positive patients who experienced ADRs during their admission 
period at tertiary care center, Rajkot from April 2020 to March 2021. All the necessary information including ADRs information was obtained from 
patient’s case record file and filled in suspected ADR reporting form. Suspected ADRs were assessed for demographic parameters and causality, 
preventability, and severity using World Health Organization (WHO) scale and Naranjo algorithm, modified Schumock and Thornton’s criteria, and 
modified Hartwig’s criteria, respectively.
Results: Out of the 100 patients there were 60 males. The mean age of the patients was 52.65±13.95 year. Fourty-six patients had comorbidities. The 
most common type of ADR was GI disorders. Among the single suspected medication, most common drug was methylprednisolone and among the 
two drugs, azithromycin was common. According to the WHO and Naranjo scale, Probable ADRs were 70% and 36%, respectively. The percentage 
for mild, moderate and severe ADRs were 44%, 39%, 17%, respectively. Eighty-six percent ADRs were definitely preventable. Fifty-one patients were 
recovered from adverse reactions.
Conclusions: Seriousness of reactions is mainly associated with co-morbid conditions. This indicates that patients with comorbidity should be closely 
monitored to avoid harmful consequences. These ADRs monitoring and reporting program will help physicians to choose their therapy sensibly and 
decrease chances of mortality in this pandemic era.
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INTRODUCTION
On December 31, 2019, a new respiratory viral disease identified in 
Wuhan, China. The disease was caused by a novel coronavirus named 
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 
On March 12, 2020, the World Health Organization (WHO) declared a 
new pandemic all over the world because cases of Coronavirus Disease 
(COVID)-19 infection rapidly increase outside China [1,2]. According 
to Data taken from WHO, on February 21, 2021, confirmed cases were 
110.7 million and over 2.4 million deaths occurred since the start of 
the pandemic [3]. The SARS-CoV-2 virus, which is an enveloped and 
single-stranded RNA virus belonging to the Coronaviridae family causes 
multiple organ system diseases in humans and animals. The signs 
and symptoms of COVID19 can varies from asymptomatic to severe 
symptoms. There is a difficulty to identify effective and safe treatments 
for COVID-19 disease. With the rapid spread of covid-19 disease in all 
over the world, the scientific authorities have developed treatment 
algorithms to treat COVID-19 infection. The treatment algorithms of 
COVID-19 are composed of medicinal drugs which have been utilized 
in preceding pandemics and the medications that have been thought 
potentially effective [4]. In response, National Institute of Health 
(NIH) provides guidelines to treat COVID-19. Antimicrobial drugs like 
hydroxychloroquine, azithromycin, remdesivir, ritonavir/ lopinavir, 
favipiravir used as antiviral drugs, immune-based drugs such as 
tocilizumab and corticosteroids and convalescent plasma with 
adjunctive therapy such as anticoagulants, Vitamin C, zinc were used [5]. 
These drugs are recommended as therapeutic drugs against COVID-19 
infection, using those drugs in pandemic is experimental, and even 
compassionate use may pose health risks due to the potential to cause 
unfavorable adverse reactions [6,7]. Adverse drug reactions (ADRs) are 
a serious public health problem and contribute to increased morbidity 
and mortality in addition to prices for each sufferer and health systems. 
Prolong hospitalization of the patient, and increase difficulties to get 
bed in the hospital for new infected patients also associated with 
ADRs [7]. Considering the limited amount of safety information for the 
treatment of COVID-19, the study aims to evaluate the ADR profile in 
patients with the COVID-19 disease.
MATERIALS AND METHODS
Study design and population
This is a descriptive, cross-sectional, prospective as well as retrospective 
type of study conducted at COVID-19 hospital of tertiary care 
teaching hospital, Rajkot after ethically approved by the institutional 
ethics committee. The population consisted of COVID-19 confirmed 
hospitalized patients who presented with ADRs and were notified by 
ADR monitoring Center, Rajkot between April 2020 and March 2021.
Data collection
All data about ADR such as demographic profile, travel history, past mediation 
history and details about ADRs, suspected medications and relevant tests 
will be collected from COVID-19 hospital and was filled in special suspected 
ADR reporting form for drugs used in prophylaxis/treatment of COVID-19 
provided by Indian Pharmacopeia Committee, Ghaziabad.
Outcome variables
Analysis of ADRs according to demographic profile, system organ 
classification (SOC), seriousness and outcome, related to travel history, 
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COVID-19 test and comorbidity, Drug-drug interaction, etc. Reaction 
terminology was confirmed with Medical Dictionary for Regulatory 
Activities (MedDRA) in vigiflow. Drug-drug interaction checked with 
https://reference.medscape.com/drug-interactionchecker. Suspected 
ADRs were assessed for causality, preventability, and severity using 
the WHO causality assessment scale and Naranjo algorithm, modified 
Schumock and Thornton’s criteria, and modified Hartwig’s criteria, 
respectively [8-11].
Statistical analysis
The results are represented as Mean±SD and percentage and number 
using Microsoft Excel (office version 2019).
RESULTS
Total 100 ADR reports were collected. Out of them, there were 60 males 
and 40 females. The mean age of patients was 52.65±13.95 years. As 
shown in Table 1 majority of ADRs noted between the age group of 
50–70 years. Majority have reverse transcription-polymerase chain 
reaction (RT-PCR) test positive (78%) as compared to rapid antigen 
test, no travel history (96%) and majority have non-serious illness 
(51%). About 54% of patients were without comorbidity and among 
comorbidity Diabetes Type-2 and Hypertension were the most common. 
About 4% ADR considered to be due to drug interaction and among 
them one interaction occurred with Enoxaparin and aspirin (Table 1).
According to SOC, ADRs related to Gastrointestinal disorders (41), 
metabolic disorders (29), bleeding disorders (16), cardiovascular disorders 
(06), General disorders (05), and psychiatric disorders (03) (Fig. 1).
As shown in (Table 2) majority of ADRs were suspected with single 
medication (69%) as compared to two medications (30%) and three 
medications (1%). Among single drug therapy, most common drug was 
methylprednisolone and among two drugs azithromycin was common. 
Most common concomitant medication prescribed were paracetamol, 
chlorpheniramine, Vitamin C, and multivitamins.
According to the WHO causality score, 70% ADRs were probable and 
30% were possible (Fig. 2). Considering Naranjo’s scale 64% were 
possible and 36% were probable. Based on the modified Hartwig 
severity scale, most of the reactions were categorized as mild (44%), 
moderate (39%), and severe (17%) in nature. According to Modified 
Schumock and Thornton’s criteria, majority of reactions were definitely 
preventable (86%) followed by probably preventable (14%) (Table 3).
Regarding management of ADRs, among suspected single drug 
medication 26 reactions were subsided on withdrawal of drug, 39 
without dose modification, and 4 on dose reduction. Among suspected 
two drugs, 3 reactions were subsided on withdrawal of both suspected 
drugs and 22 without dose modification and 5 reactions were subsided 
with one drug withdrawal while other suspected drug continued 
Table 2: Distribution of ADRs according to suspected medication
Type of suspected 
drug therapy
No. of ADRs 
(%) (n=100)
Type of suspected drugs




















Three drug therapy 1 (1%) Azithromycin (1)
Heparin (1)
Ceftriaxone (1)
Table 3: Distribution of ADRs according to causality, severity, 
and preventability









Preventability (Modified Schumock and  
Thornton’s criteria)
Definitely preventable 86 (86%)
Probable preventable 14 (14%)
Table 1: Characteristics of the patients (n=100) 












Type of COVID-19 test
RT-PCR 78 (78%)

































































No.of ADRs (n = 100)
Fig. 1: Distribution of adverse drug reactions according to system 
organ classification
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The male predominance (60%) in COVID-19 ADR reporting is steady 
with the consequences of an observe achieved through Zekarias 
et al. [15]. The mean age of patients for ADRs was 52.65±13.95 years. 
Almost comparable end result visible with a study done by Sun et  al. [16] 
our result confirmed that majority patients were tested positive by RT-
PCR and no travel history. Elderly populations are followed through 
comorbidity and polypharmacy leading to increases in unfavorable 
drug reactions (ADRs) [17]. Our result confirmed that majority ADRs 
occurred in patients whose age was between 50 and 70 years. Possible 
reasons could be the changes in pharmacokinetics with advancing age 
or Disease presentation-older age group patients were developing 
complications or leading to hospital admissions.
Drug-drug interactions occurring in the course of COVID-19 treatment 
and co-morbidities could lead to ADRs, which causes increasing the 
risk of hospitalization, prolonged time to recovery, or death on some 
cases [18]. In our observation, comorbidity has been found in 46% of 
cases of ADR and drug-drug interaction was observed in 4% of cases.
According to SOC most common ADRs associated with GIT 
disorders (41%), which is inconsistent with the results of a study 
performed by Crescioli et al. [19]. Among them, Diarrhea was the 
most common symptom and suspected medication was antibiotics 
that is established truth that diarrhea is common adverse effect of 
antibiotics [20]. Other study reported that ADRs cited with two or 
more suspected drug therapy [19]. In comparison to this, our result 
confirmed that ADRs cited with single suspected medication (69%) 
were higher than two (30%) and three (1%) suspected drug therapy. 
Methylprednisolone is more common with single suspected and 
azithromycin is more common with two suspected drug therapy. 
Steroids are the principle motive of drug-induced hyperglycemia. 
They not only exacerbate hyperglycemia in patients with known 
diabetes mellitus but also cause DM in patients without documented 
hyperglycemia before the initiation of glucocorticoids therapy [21,22]. 
Also in our study metabolic disorders noted the second most common 
ADRs and among them, hyperglycemia was the most common 
symptom.
Considering causality assessment our end result showed that 70% 
ADRs were probable and 30% were possible as per the WHO causality 
assessment scale which changed into contrary from the questionary 
primarily based totally Naranjo’s algorithm, where 36% ADRs were 
probable and 64% were possible and additionally contrary to observe 
performed through Melo et al. where 19.8% ADRs were probable 
and 67.4% were possible. According to Hartwig’s severity scale, mild 
ADRs have been described as those which does not by itself require 
prolongation of hospitalization and could be managed by simple 
measures, moderate were those ADRs which needed prolongation of 
hospital stay of the patient for treatment of the same and severe were 
life-threatening ADRs [23].
According to our observations, most of the unfavorable drug 
reactions were categorized as mild (44%) and moderate (39%). Only 
17% of ADRs have been categorized as severe ADRs. According to 
Preventability (Modified Schumock and Thornton’s) criteria majority 
have been actually definitely preventable ADRs (86%). Considering 
management, we found that the majority of ADRs abated on without 
dose modification whether suspected medication was single or 
two drugs. Finally, concerning final results of ADRs majority were 
recovered (51%) and recovering phase (33%). Similar result observed 
in study performed by Melo et al. wherein 62.3% recovered and 21.7% 
in recovering phase.
CONCLUSION
Comorbid and elderly patients should be closely monitored for ADRs 
to avoid harmful consequences in this COVID-19 pandemic situation. 
The pharmacovigilance program of India (PvPI) will work as important 
tool to help physicians to choose their therapy sensibly and decrease 
chances of mortality in this pandemic era.
Table 4: Distribution of ADRs according to type of management
Suspected 
medication
Reaction abated on No. of ADRs 
(%) (n=100)




Dose reduction 4 (4%)







Three drugs Without dose 
modification
1 (1%)
without dose modification. Among suspected three-drug medication 1 
reaction subside without dose modification (Table 4).
Regarding outcome of ADR, recovered (51%), recovering (33%), not 
recovered (6%), fatal (6%), and unknown (4%) (Fig. 3).
DISCUSSION
Since COVID-19 influences multi-organ systems, the infection and its 
treatment may also motive many adverse effects instead of aspect effects [4]. 
There is a determined want to pick out powerful treatment for coronavirus 
disorder. Most drugs recently used in this COVID-19 pandemic are 
repurposed antiviral and immunomodulatory drugs [12]. WHO in addition 
to the European Medicines Agency (EMA) have indicated the shortage of 
proof helping the efficacy and safety of any medicine in COVID-19 [13,14]. 
Hence, this study examined ADR occurred with experimental drugs used 












Recovered Recovering Fatal Not recovered Unknown
Fig. 3: Outcome of adverse drug reaction
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